CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 17, 2020—Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2 virus.
The Elecsys Anti-SARS-CoV-2 immunoassay is an in vitro test that uses human serum and plasma drawn from a blood sample to detect antibodies and determine the body’s immune reaction to SARS-CoV-2. Hospitals and reference laboratories can run the test on Roche’s Cobas e analyzers, which can provide results in about 18 minutes, with a test throughput of up to 300 tests per hour, depending on the analyzer.
Pages: 1 2